In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products
The development of generic, single‐entity, drug-device combination products for orally inhaled drug products is challenging in part because of the complex nature of device design characteristics and the difficulties associated with establishing bioequivalence for a locally acting drug product delive...
Saved in:
Main Authors: | Ross L. Walenga (Author), Andrew H. Babiskin (Author), Liang Zhao (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report
by: Ross L. Walenga, et al.
Published: (2023) -
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report
by: Ming‐Liang Tan, et al.
Published: (2023) -
Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%
by: Eleftheria Tsakalozou, et al.
Published: (2021) -
In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
by: Changzhi Shi, et al.
Published: (2021) -
Generic Drug Product Development Bioequivalence Issues
by: Iain J. McGilveray
Published: (2008)